Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: A retrospective study

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 4089-4096

  Salgado, Mercedes ^a   Reboredo, Margarita ^b   Mendez, Juan Carlos ^c   Quintero, Guillermo ^d   Pellón, María Luz ^e   Romero, Carlos ^f   Jorge, Mónica ^g   Montes, Ana Fernández ^a   Valladares Ayerbes, Manuel ^b   Ramos, Manuel ^c   Varela, Silvia ^d   Alonso, Miguel Ángel ^a  

^a University Complex Hospital of Ourense   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c Regional Cancer Center of Galicia   (Spain)

^d University Hospital Lucus Augusti   (Spain)

^e Universidad de La Coruña   (Spain)

^f HOSPITAL POVISA   (Spain)

^g HOSPITAL XERAL CÍES   (Spain)

Author keywords

Capecitabine; Colorectal cancer; Gemcitabine; Refractory

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CAPECITABINE; COLORECTAL CANCER; GEMCITABINE; REFRACTORY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84885015751     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. de GA, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le BN, Louvet C, Hendler D, de BF, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
4. Cunningham D and Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26: 6-12, 1999.
5. Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718, 2007.
6. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB, III: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
8. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23: 3697-3705, 2005.
9. Van CE, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M and Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007.
10. Mani S, Kugler JW, Knost JA, Sciortino DF, Gibbons J, Garcia JC, Ansari RH, Schilsky RL and Vokes EE: Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer. Invest New Drugs 16: 275-278, 1998.
11. Moore DF Jr., Pazdur R, Daugherty K, Tarassoff P and Abbruzzese JL: Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10: 323-5, 1992.
12. Shulz L, Schalhorn A, Wilmanns W, Heinemann V..Synergistic interaction of gemcitabine and 5-FU in colon cancer cells. Proc Am Soc Clin Oncol (Meeting Abstracts) (1), abstract 965. 1998.
13. Schilsky RL: Pharmacology and clinical status of capecitabine. Oncology 14: 1297-1306, 2000.
14. Cassidy J, Twelves C, Van CE, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P and Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575, 2002.
15. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO and Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
16. Van CE, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C and Harper P: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
17. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S and Viola M: Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol 18: 3553-7, 2000.
18. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL and Ratain MJ: Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20: 582-587, 2002.
19. Fernández Y, Vieitez JM, Fra J, Palacio, B. Mareque, E. Uña, J. M. Buesa, A. J. Lacave: Capecitabine plus gemcitabine in heavily-treated colorectal cancer. Results of an exploratory study. J Clin Oncol 22(14S): abstract 3679, 2004.
20. Pachon V, Garcia-Alfonso P, Iglesias L, Siso I, Abad G, Khosravi P, Diaz V and Perez-Manga G: Gemcitabine plus continuous infusion of 5-FU for heavily pre-treated advanced colorectal cancer patients. Phase I/II study. J Clin Oncol 23(16S Part I): abstract 3735, 2005.
21. Bitossi R, Sculli CM, Tampellini M, Alabiso I, Brizzi MP, Ferrero A, Ottone A, Bellini E, Gorzegno G, Berruti A and Dogliotti L: Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 28: 3055-3060, 2008.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
23. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
24. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E and Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334, 2008.
25. Merl M, Hoimes C, Pham T and Saif MW: Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: Poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). Expert Opin Investig Drugs 18: 1257-1264, 2009.
26. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J and Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24: 3354-3360, 2006.
27. Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK and Lee JS: Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: A retrospective analysis. Med Oncol 26: 32-37, 2009.
28. Lievre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepere C, Bachet JB, Portales F, Vaillant JN, Ychou M and Rougier P: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: A retrospective study. BMC Cancer 9: 347, 2009.
29. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F and Isacoff W: Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 8(Suppl 1): s50-s52, 2004.
30. Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ and Kim YS: Bevacizumab as a second-or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 18: 1104-119, 2012.
31. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van HG, Wierzbicki R, Langer C and Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
32. Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN and Strimpakos AS: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): A single institution experience. Anticancer Res 31: 2971-2974, 2011.
33. Rosati G, Rossi A, Germano D, Reggiardo G and Manzione L: Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: A phase II study. Anticancer Res 23: 2981-2985, 2003.
34. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J and Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514, 2005.
35. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S and Hoff PM: A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48: 820-826, 2012.
36. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA and Fuchs CS: Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18: 377-378, 2013.
37. Grothey A, Van CE, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A and Laurent D: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381: 303-312, 2013.
38. Kim SY, Hong YS, Kim BC, Park JW, Choi HS, Jeong SY, Kim DY, Hong CW, Sohn DK and Jung KH: A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. Invest New Drugs 27: 269-2674, 2009.
39. Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L and Hurwitz HI: A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 16: 1131-1137, 2011.
40. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L and Richards DA: Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second-or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 29: 4394-4400, 2011.
41. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T and Ohtsu A: TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13: 993-1001, 2012.